Side-by-side · Research reference

N-Acetyl Epitalon AmidatevsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BPhase 3HUMAN-REVIEWED14/43 cited

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

N-Acetyl Epitalon Amidate

Sermorelin

Primary target

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Pituitary GHRH receptorWalker 1994

Pathway

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

—

Yes — short pulse preserves feedback

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

N-Acetyl Epitalon Amidate

Sermorelin

Standard dose

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

100–500 mcg per injectionMolteno 2013

Frequency

Not specified in candidate papers

Once daily, pre-sleep

Evidence basis

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Cell culture protocol

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

—

Duration

Chronic treatment in aging culture

Sustained effect through late passages.

8–12 weeks per cycle

Modification stability

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

—

Lower / starter dose

—

100 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep, fasted preferred

Half-life

—

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

04Side Effects & Safety

Parameter

N-Acetyl Epitalon Amidate

Sermorelin

Human safety data

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

—

Theoretical telomerase risk

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

—

In vitro observations

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

—

Injection site reaction

—

Mild erythema, transient pain

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Glucose handling

—

Generally neutral

Absolute Contraindications

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

N-Acetyl Epitalon Amidate

Sermorelin

1. Route

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Reconstitution

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

SQ — abdomen or thigh. Rotate sites.

3. Storage

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

Pre-sleep, fasted.

4. Clinical protocols

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994